Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1975 3
1976 1
1977 2
1978 2
1979 1
1980 6
1981 5
1982 3
1983 8
1984 8
1985 5
1986 6
1987 3
1988 6
1989 7
1990 8
1991 7
1992 10
1993 7
1994 9
1995 20
1996 17
1997 15
1998 21
1999 25
2000 11
2001 34
2002 25
2003 21
2004 24
2005 28
2006 31
2007 35
2008 40
2009 43
2010 41
2011 46
2012 49
2013 59
2014 46
2015 47
2016 47
2017 39
2018 44
2019 50
2020 47
2021 70
2022 84
2023 83
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

1,116 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Favorable Non-Hodgkin Lymphoma"
Page 1
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Martínez-Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez-Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Hutchings M, et al. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19. J Clin Oncol. 2021. PMID: 33739857 Free PMC article. Clinical Trial.
This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (Gpt) to reduce toxicity, are presented. ...Of 63 patients with CR, 53 (84.1%) have o …
This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for s …
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
Shustov A, Soma L. Shustov A, et al. Cancer Treat Res. 2019;176:127-144. doi: 10.1007/978-3-319-99716-2_6. Cancer Treat Res. 2019. PMID: 30596216 Review.
While histologic features of ALCL subtypes have significant overlap, genomic studies suggest the unique pathophysiology and molecular events of tumorigenesis. As a group, ALCLs are rare among non-Hodgkin lymphomas comprising 1-3% overall. There seems to be age and g …
While histologic features of ALCL subtypes have significant overlap, genomic studies suggest the unique pathophysiology and molecular events …
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM. Flinn IW, et al. J Clin Oncol. 2019 Apr 20;37(12):984-991. doi: 10.1200/JCO.18.00605. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811293 Free PMC article. Clinical Trial.
PURPOSE: The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosp …
PURPOSE: The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plu …
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.
Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, Marcus R, Kimby E, Herold M, Sebban C, Gyan E, Foon K, Nielsen T, Vitolo U, Salles GA, Shi Q, Flowers CR. Casulo C, et al. Blood. 2022 Mar 17;139(11):1684-1693. doi: 10.1182/blood.2020010263. Blood. 2022. PMID: 34614146 Free PMC article.
Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. ...This is the largest pooled analysis of clinical tri …
Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progr …
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Zammarchi F, Corbett S, Adams L, Tyrer PC, Kiakos K, Janghra N, Marafioti T, Britten CE, Havenith CEG, Chivers S, D'Hooge F, Williams DG, Tiberghien A, Howard PW, Hartley JA, van Berkel PH. Zammarchi F, et al. Blood. 2018 Mar 8;131(10):1094-1105. doi: 10.1182/blood-2017-10-813493. Epub 2018 Jan 3. Blood. 2018. PMID: 29298756 Free article.
Human CD19 antigen is a 95-kDa type I membrane glycoprotein in the immunoglobulin superfamily whose expression is limited to the various stages of B-cell development and differentiation and is maintained in the majority of B-cell malignancies, including leukemias and non- …
Human CD19 antigen is a 95-kDa type I membrane glycoprotein in the immunoglobulin superfamily whose expression is limited to the various sta …
Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART).
Maguire R, McCann L, Kotronoulas G, Kearney N, Ream E, Armes J, Patiraki E, Furlong E, Fox P, Gaiger A, McCrone P, Berg G, Miaskowski C, Cardone A, Orr D, Flowerday A, Katsaragakis S, Darley A, Lubowitzki S, Harris J, Skene S, Miller M, Moore M, Lewis L, DeSouza N, Donnan PT. Maguire R, et al. BMJ. 2021 Jul 21;374:n1647. doi: 10.1136/bmj.n1647. BMJ. 2021. PMID: 34289996 Free PMC article. Clinical Trial.
SETTING: Twelve cancer centres in Austria, Greece, Norway, Republic of Ireland, and UK. PARTICIPANTS: 829 patients with non-metastatic breast cancer, colorectal cancer, Hodgkin's disease, or non-Hodgkin's lymphoma receiving first line adjuvant c …
SETTING: Twelve cancer centres in Austria, Greece, Norway, Republic of Ireland, and UK. PARTICIPANTS: 829 patients with non-metastati …
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.
Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Batlevi CL, et al. Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z. Blood Cancer J. 2020. PMID: 32678074 Free PMC article.
Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score was developed to predict survival at diagnosis, yet it remains unknown whether increase in FLIPI score following an initial observation period is associated with less- …
Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score was developed to predict survival at diagnos …
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodgkin lymphoma and two (5%) of 43 patients with solid tumours. INTERPRETATION: Tazemetostat showed a favourable safety profi …
Durable objective responses, including complete responses, were observed in eight (38%) of 21 patients with B-cell non-Hodg …
Bacterial infection and non-Hodgkin's lymphoma.
Melenotte C, Mezouar S, Mège JL, Gorvel JP, Kroemer G, Raoult D. Melenotte C, et al. Crit Rev Microbiol. 2020 May;46(3):270-287. doi: 10.1080/1040841X.2020.1760786. Epub 2020 May 15. Crit Rev Microbiol. 2020. PMID: 32412856 Review.
Nonetheless, Helicobacter pylori, Chlamydia psittaci, Coxiella burnetii, Borrelia burgdorferi and Campylobacter jejuni are bacteria that can be associated with non-Hodgkin's lymphoma (NHL), the most common haematologic malignancy. Here, we review the evidence …
Nonetheless, Helicobacter pylori, Chlamydia psittaci, Coxiella burnetii, Borrelia burgdorferi and Campylobacter jejuni are bacteria that can …
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Davis KL, et al. Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17. Lancet Oncol. 2020. PMID: 32192573 Free PMC article. Clinical Trial.
Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the following disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin lymphoma, non-Hodgkin lymph …
Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the following disea …
1,116 results